Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.60 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815385 | 0.96 | ESR1 (0.67) | ESR1ESR2ARAKR1C3HSD17B1 | |
| SCHEMBL18388215 | 0.88 | ESR1 (0.52) | ESR1ESR2ARAKR1C3HSD17B1 | |
| SCHEMBL1254675 | 0.88 | ESR1 (0.52) | ESR1ESR2ARAKR1C3HSD17B1 | |
| SCHEMBL3440740 | 0.87 | ESR1 (0.60) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL20821889 | 0.86 | ESR1 (0.55) | ESR1ESR2ARAKR1C3HSD17B1 | |
| SCHEMBL12917725 | 0.83 | ESR1 (0.56) | ESR1ESR2ARHSD17B1HSD17B2 | |
| SCHEMBL17431967 | 0.83 | ESR1 (0.56) | ESR1ESR2ARHSD17B1HSD17B2 | |
| SCHEMBL2246071 | 0.83 | ESR1 (0.60) | ESR1ESR2ARHSD17B1HSD17B2 | |
| SCHEMBL38659424 | 0.82 | ESR1 (0.70) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL28226426 | 0.82 | ESR1 (0.70) | ESR1ESR2HSD17B1HSD17B2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2586764-B1 | COMPOUND HAVING BRANCHED ALKYL OR BRANCHED ALKENYL, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL ELEMENT | JNC CORP (JP) | 2019-09-18 | — | — | EP | disclosed |
| EP-3368637-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-07-17 | — | — | US | disclosed |
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20180030347-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20180030347-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20170357131-A1 | LIGHT MODULATION ELEMENT | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170351130-A1 | LIGHT MODULATION ELEMENT | MERCK PATENT GMBH (DE) | 2017-12-07 | — | — | US | disclosed |
| US-20170343847-A1 | LIGHT MODULATION ELEMENT | MERCK PATENT GMBH (DE) | 2017-11-30 | — | — | US | disclosed |
| EP-2855631-B1 | MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2017-09-20 | — | — | EP | disclosed |
| EP-2116522-A1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING CF<SB>2</SB>O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | Chisso Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2098583-A2 | Optically isotropic liquid crystal medium and optical device | Chisso Corporation (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098583-A2 | Optically isotropic liquid crystal medium and optical device | Chisso Corporation (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20090135368-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | CHISSO CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090135368-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | CHISSO CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090135368-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | CHISSO CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7385067-B2 | Process for the preparation of compounds having a CF2O bridge | MERCK PATENT GMBH (DE) | 2008-06-10 | — | — | US | disclosed |
| US-7385067-B2 | Process for the preparation of compounds having a CF2O bridge | MERCK PATENT GMBH (DE) | 2008-06-10 | — | — | US | disclosed |
| EP-1762605-A1 | Naphthalene compound with terminal hydrogen, liquid crystal composition including the compound, and LCD device including the liquid crystal composition | Chisso Petrochemial Corporation (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | CHISSO PETROCHEMICAL CORPORATION (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | LEF1, CFD, FOXO1 | ESR1 1826/4885ESR2 1051/4885AR 3460/4885 |
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | PIEZO1, ROCK1, RCC1 | ESR1 4307/4885ESR2 4433/4885AR 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.